Prosecution Insights
Last updated: April 19, 2026
Application No. 17/429,906

METHODS FOR PREDICTING THE RISK OF PROGRESSION AND PHARMACOLOGICAL RESPONSE OF A HUMAN SUBJECT SUFFERING FROM RELAPSING-REMITTING MULTIPLE SCLEROSIS

Non-Final OA §112
Filed
Aug 10, 2021
Examiner
HANEY, AMANDA MARIE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BIONOU RESEARCH S.L.
OA Round
3 (Non-Final)
36%
Grant Probability
At Risk
3-4
OA Rounds
3y 7m
To Grant
80%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allow Rate
256 granted / 702 resolved
-23.5% vs TC avg
Strong +44% interview lift
Without
With
+44.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
57 currently pending
Career history
759
Total Applications
across all art units

Statute-Specific Performance

§101
22.8%
-17.2% vs TC avg
§103
23.5%
-16.5% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
31.6%
-8.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 702 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 14, 2025 has been entered. Applicant’s remarks and amendments have been fully and carefully considered but are not found to be sufficient to put the application in condition for allowance. Any rejections or objections not reiterated herein have been withdrawn. Claims 12-29, 32, 34, and 36-40 are currently pending. Claims 12-28 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on October 11, 2024. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 29, 32, 34, and 36-40 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. In the instant case the specification does NOT appear to provide support for the amendment of claim 29 to recite: ii. at least one labelled probe comprising SEQ ID NO: 16, a 5' end fluorescent reporter, and a 3' end quencher; iii. at least one labelled probe comprising SEQ ID NO: 17, a 5' end fluorescent reporter, and a 3' end quencher; The specification has been reviewed for support for the claims as amended. The specification teaches the following: [0055] In yet another preferred embodiment of the first or second aspect of the invention or of any of the preferred embodiments of the invention, the amplification reaction is carried out by means of a real-time polymerase chain reaction. Preferably, the detection of the amplification product is carried out by means of a fluorescent intercalating agent. Even more preferably, the detection of the amplification product(s) is carried out by means of a labeled probe, wherein the probe preferably comprises at its 5′ end a reporter pigment and at its 3′ end a “quencher” pigment or silencer or buffering agent. Preferably, in the case of Bilophila, the amplification reaction is carried out by using the following primers of SEQ ID NO 16 and 17: Bil1 F GGT ATG TTC GAT CCG GCT ATC R TGT TTT CCC GAC CAT CTT CC While the specification discloses performing an amplification reaction using SEQ ID NOs: 16 and 17 as primers, the specification does not provide specific support for using SEQ ID NOs: 16 and 17 as probes to detect an amplification product. Further the specification does not teach that SEQ ID NOs: 16 and 17 may comprise a 5' end fluorescent reporter and a 3' end quencher. The written description requirement prevents an applicant from claiming subject matter that was not adequately described in the specification as filed. New or amended claims which introduce elements or limitations that are not supported by the as-filed disclosure violate the written description requirement. See, e.g., In re Lukach, 442 F.2d 967, 169 USPQ 795 (CCPA 1971) (subgenus range was not supported by generic disclosure and specific example within the subgenus range); In re Smith, 458 F.2d 1389, 1395, 173 USPQ 679, 683 (CCPA 1972) (an adequate description of a genus may not support claims to a subgenus or species within the genus). Requirement for Information 4. Applicant and the assignee of this application are required under 37 CFR 1.105 to provide the following information that the examiner has determined is reasonably necessary to the examination of this application. Claim 29 has been amended to recite: ii. at least one labelled probe comprising SEQ ID NO: 16, a 5' end fluorescent reporter, and a 3' end quencher; iii. at least one labelled probe comprising SEQ ID NO: 17, a 5' end fluorescent reporter, and a 3' end quencher; The required information is as follows: a. Please disclose if SEQ ID NO: 16 has the same nucleotide sequence as a naturally occurring Bilophila nucleic acid sequence. If so, how did the inventors get possession of this naturally occurring Bilophila nucleic acid sequence. b. Please provide details on how the inventors designed the primer of SEQ ID NO: 16. c. Please describe how the primers of SEQ ID NOs: 16 and 17 relate to the target Bilophila regions of SEQ ID NOs: 10-12. If possible, please provide an alignment showing how the primers are able to amplify the regions comprising SEQ ID NOs: 10-12. The applicant is reminded that the reply to this requirement must be made with candor and good faith under 37 CFR 1.56. Where the applicant does not have or cannot readily obtain an item of required information, a statement that the item is unknown or cannot be readily obtained may be accepted as a complete reply to the requirement for that item. This requirement is an attachment of the enclosed Office action. A complete reply to the enclosed Office action must include a complete reply to this requirement. The time period for reply to this requirement coincides with the time period for reply to the enclosed Office action. 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA HANEY whose telephone number is (571)272-8668. The examiner can normally be reached Monday-Friday, 8:15am-4:45pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Shen can be reached on 571-272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMANDA HANEY/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Aug 10, 2021
Application Filed
Nov 26, 2024
Non-Final Rejection — §112
Feb 28, 2025
Response Filed
Mar 10, 2025
Final Rejection — §112
Jun 27, 2025
Interview Requested
Jul 09, 2025
Response after Non-Final Action
Jul 09, 2025
Examiner Interview Summary
Aug 14, 2025
Request for Continued Examination
Aug 15, 2025
Response after Non-Final Action
Sep 16, 2025
Examiner Interview (Telephonic)
Sep 18, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12577612
DEVICES AND METHOD FOR DETECTING AN AMPLIFICATION EVENT
2y 5m to grant Granted Mar 17, 2026
Patent 12546786
CIRCULATORY BIOMARKERS FOR PLACENTAL OR FETAL HEALTH
2y 5m to grant Granted Feb 10, 2026
Patent 12545957
METHOD OF DETERMINING ENDOMETRIAL RECEPTIVITY AND APPLICATION THEREOF
2y 5m to grant Granted Feb 10, 2026
Patent 12516390
Methods and Systems for Predicting Whether a Subject Has a Cervical Intraepithelial Neoplasia (CIN) Lesion from a Suspension Sample of Cervical Cells
2y 5m to grant Granted Jan 06, 2026
Patent 12503733
METHODS OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
36%
Grant Probability
80%
With Interview (+44.0%)
3y 7m
Median Time to Grant
High
PTA Risk
Based on 702 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month